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Bortezomib: A New Promising Therapy for 
Early Antibody-Mediated Rejection After Liver 
Transplantation?
Marcio F. Chedid, MD, PhD1,2 and Emilio Rodrigo, MD, PhD3
Antibody-mediated rejection (AMR) after ABO-compatible (ABOc) liver transplantation (LTx) is a 
rare phenomenon. When compared with ABOc LTx, ABO-
incompatible (ABOi) LTx is related to a higher incidence of 
complications, especially AMR, hepatic artery thrombosis, 
and also biliary complications.1 ABOi LTx is usually accom-
plished through living liver donation and rarely performed in 
the Western World. However, ABOi LTx is a relatively com-
mon of practice in Eastern countries where deceased donation 
is scarce.
As a preparation to ABOi LTx, plasmapheresis (PP) or 
immunoadsorption with low-dose intravenous immunoglob-
ulin (IVIG) replacement is usually necessary in order to lower 
anti-A and anti-B antibodies against the potential live donor. 
The CD20 inhibitor rituximab is also utilized along PP.2
Most rejection episodes following ABOc are cellular rejec-
tions. The liver allograft is relatively resistant to humoral 
response. Thus, AMR following ABO-c LTx is exceedingly 
rare.3,4 Some of the AMR following ABOc LTx cases are sec-
ondary to anti-HLA antibodies in positive XM LTx cases.3
The diagnosis of AMR following ABOc LTx is challenging. 
In this setting, AMR is usually triggered by anti-HLA antibod-
ies. However, due to the rarity of AMR in the setting of ABOc 
LTx, most groups do not perform pre-LTx crossmatch. In LTx 
recipients, AMR may have a variety of clinical presentations, 
including one or more of the following: elevation of liver 
enzymes, hepatic artery thrombosis, or even biliary complica-
tions. AMR is diagnosed by the following 3 criteria: (1) clini-
cal signs of graft dysfunction, (2) histopathology indicative 
of acute injury ± positive C4d stain, and (3) presence of HLA 
donor-specific antibodies (DSA) or anti-A/anti-B antibodies.
The standard management of AMR following kidney 
transplantation (KTx) (either ABOc or ABOi) relies on PP 
or immunoadsorption with IVIG along with rituximab.3 This 
therapy is driven to both reduce the burden of circulating 
anti-HLA antibodies and limit their production. Although 
this management is usually successful for AMR following 
KTx, its efficacy in the setting of AMR following LTx seems 
controversial.3,4 Ronstron et al4 obtained complete control of 
AMR employing PP and rituximab. Conversely, Chan et al3 
were not able to rescue any of the 2 patients treated with PP 
and rituximab. Similar findings were reported by Lee et al5 
for 3 patients. Moreover, all these patients experienced death 
following loss of the liver allograft.3,5
Bortezomib inhibits the chymotrypsin-like site of the 20S 
proteolytic core within the 26S proteasome, thereby induc-
ing cell-cycle arrest and apoptosis on plasma cells. There 
have been few reports of the use of bortezomib as a treat-
ment for AMR following ABOc LTx. Paterno et al6 reported 
on 3 cases of successful treatment of AMR following ABOc 
LTx by bortezomib. Chan et al3 and Koch et al7 described 1 
additional case each. In the latter case, bortezomib was able 
to rescue an AMR episode that was resistant to splenectomy. 
Lee et al5 described the largest series of bortezomib utilization 
for refractory AMR after ABOc LTx. The authors achieved 
AMR control in 3 out of the total 6 patients receiving this 
approach (including 1 case of AMR secondary to ABOi LTx). 
The remaining 3 patients lost their liver allografts and experi-
enced a fatal outcome.5
In this issue of Transplantation Direct, Tajima et al8 report 
on the use of bortezomib as a successful treatment for early 
refractory AMR after ABOi LTx in an adult patient. The 
authors were not able to obtain control of the AMR with 
readministration of rituximab, steroid-pulse, IVIG, and PP in 
the posttransplant period. Only after adding bortezomib on 
posttransplant day 9, the authors obtained complete resolu-
tion of the AMR episode. Of note, bortezomib achieved a fast 
and intense reduction of CD19/20 cells and antibody titers at 
an early stage after LTx, being introduced only after therapies 
were not able to control the humoral response.
Before the report of Tajima et al, there was only 1 prior case 
reporting the use of bortezomib for the treatment of AMR in 
an ABOi LTx recipient.5 The drug was also able to control 
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rejection in that prior literature case. Thus, the importance 
of the report of Tajima et al resides on both its rarity and its 
successful outcome. Although there are no randomized con-
trolled trials of bortezomib in early AMR either in KTx or 
LTx, some KTx studies comparing bortezomib use to treat 
AMR versus a control group have shown higher AMR success-
ful treatment rates, better kidney graft survival, and improved 
renal function for the KTx patients who received bortezomib.9
From the KTx studies, we would highlight 2 issues that 
could be extrapolated to LTx and, specifically, to the Tajima 
et al reported case. First, KTx recipients with early post-
transplant AMR were more likely to have a better response 
to bortezomib therapy than those with late AMR episodes.10 
Second, desensitization studies have shown a limited efficacy 
of bortezomib monotherapy to reduce DSA. By contrast, bort-
ezomib contributed significantly to reducing DSA associated 
with other therapies such as PP, rituximab, steroids, and/or 
IVIG.9 Adding bortezomib to PP, IVIG, steroids, and rituxi-
mab could be a good option for treating early AMR both in 
ABOc and ABOi LTx.
Due to its rarity and variety of clinical presentations, AMR 
following ABOc may be misdiagnosed or diagnosed too late 
in its course. Otherwise, maybe some cases of suspected AMR 
were indeed some other diagnosis, and therefore did not 
respond to antirejection treatment. Those difficulties might be 
1 reason for the inconsistent effects of therapy for AMR in 
this setting.
Unlike KTx, in which graft loss may be treated with dialy-
sis, failure of the liver allograft is a catastrophic event that 
results in patient death unless a deceased donor becomes 
readily available. In several of the reports cited above, liver 
allograft failure was followed by patient death. Thus, AMR 
following LTx is an event of high lethality.
Based solely on small case series and single case reports, 
it seems that the use of bortezomib might be effective for 
AMR refractory to the standard management (PP with rituxi-
mab) both in ABOc and ABOi LTx, although not all patients 
responded to this therapy.5 Perhaps some of these failures 
could be attributed to delayed start of the drug. Thus, bort-
ezomib should be considered as a potential option in every 
case of AMR after LTx.
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